HOME >> BIOLOGY >> NEWS
Introgen publishes preclinical findings demonstrating the potent anti-tumor properties of INGN 241 study featured on the cover of Molecular Medicine

Austin, TX, May 10, 2001- Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today the publication of its preclinical studies in the current issue of Molecular Medicine demonstrating the potent anti-tumor effects of INGN 241 (an adenoviral vector encoding the mda-7 gene) in three of the most prevalent human cancers, breast, lung and colorectal.

The study also demonstrates, for the first time, that MDA-7 protein is released from cancer cells treated with Adenoviral-mda7. The lead author of the publication is Abner Mhashilkar, Ph.D., project leader of Introgens mda-7 program. The cover of Molecular Medicine featured a photomicrograph which demonstrates secretion of MDA-7 protein from INGN 241 treated cells, a result which may enhance the potency of INGN 241 therapy.

The research and paper are the result of the efforts of an international team of collaborators, including scientists from The University of Texas M. D. Anderson Cancer Center, the Imperial Cancer Research Technology in the United Kingdom, Corixa Corporation and Columbia University College of Physicians and Surgeons. The study was funded in part by grant R43 CA86587 from the National Cancer Institute.

We have previously shown that INGN 241 will selectively kill lung tumor cells by inducing the cells to commit suicide, a process known as apoptosis, said Sunil Chada, Ph.D., Introgens director of research and development and senior author of the manuscript. These new functional studies indicate that the mda-7 gene has tumor suppressor activity in some of the most prevalent human cancers. Introgens research also demonstrates that the MDA-7 protein is secreted. These unique properties of INGN 241 suggest that it may be a potent anti-tumor agent for local-regional applications, and potentially for the systemic treatment of cancer.

The studies involved functional biological assays coupled with genomic analytic tools. These studies indicated that INGN 241 suppressed growth in 19 out of
'"/>

Contact: Andi Wakayama
a.wakayama@noonanrusso.com
415-677-4455 ext 252
Noonan/Russo Communications
9-Apr-2001


Page: 1 2 3 4

Related biology news :

1. Introgens gene drug demonstrates tumor growth control
2. New family of 10 cancer related genes discovered by NCI, University of Texas and M.D. Anderson researchers; licensed by Introgen
3. Introgen Therapeutics reports advances in RPR/INGN 201 clinical program for treatment of advanced cancers
4. Introgen Therapeutics reports progress in gene therapy studies at annual ASCO meeting
5. Wiley publishes Welcome to the Genome: A Users Guide to the Genetic Past, Present, and Future
6. Warren Pharmaceuticals publishes results of preclinical evaluation
7. Professor publishes book on historic mosquito wars
8. AGI publishes 42nd edition of Directory of Geoscience Departments
9. International HapMap Consortium publishes scientific strategy
10. Ingenium publishes biological characterization of first mouse model for kidney stones
11. OHSU researcher publishes first measurements of free-base nicotine in cigarette smoke

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/2/2018)... ... August 02, 2018 , ... RxS LLC (“RxS”), a privately ... announced that Mark Jara, principal of the organization, has been named to PharmaVOICE ... Individuals named to PharmaVOICE 100 are leaders who drive the industry forward and ...
(Date:8/1/2018)... Md. (PRWEB) , ... August 01, 2018 , ... ... software portfolio, announces the release of Limfinity® version 7.1. Limfinity® is the software ... to Limfinity® itself creates new possibilities for both current users and the future ...
(Date:8/1/2018)... JUPITER, Fla. (PRWEB) , ... August 01, 2018 ... ... “YOU” the staff NP, PA’s, RN’s, LPN’s, MA's and Administrative staff. , This ... processing of all the biologics. The course will expose your staff to regenerative ...
Breaking Biology News(10 mins):
(Date:7/25/2018)... ... July 25, 2018 , ... ... managing clinical trial patient and supplies data through its flagship IXRS® 3 ... IRT: Best Practices.” , This podcast features both Almac thought leaders and outside ...
(Date:7/24/2018)... ... July 24, 2018 , ... R3 Stem Cell is ... Vegas. The treatments are offered by Double Board Certified providers, with outcomes significantly improving ... with suppressing symptoms, but have done nothing to help repair and regenerate damaged lung ...
(Date:7/22/2018)... ... July 19, 2018 , ... CallTower ... joined their team. With more than ten years of strategic, result-oriented Channel experience ... expertise as CallTower’s Channel Director for the Southwest and Mountain region. , As ...
(Date:7/22/2018)... ... July 20, 2018 , ... ... automation and IT solutions with 150 employees on both the east and west ... Program. Superior Controls met the high criteria for application expertise, operational excellence ...
Breaking Biology Technology:
Cached News: